EFFICACY OF THE RXR AGONIST BEXAROTENE IN PRECLINICAL MODELS OF ADENOCARCINOMA OF THE LUNG AND SMALL CELL LUNG CANCER

被引：0
|
作者：
Wang, Yian [1 ]
Lubet, Ronald A. [2 ]
You, Ming [3 ]
机构：
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63130 USA
[2] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[3] Med Coll Wisconsin, Ctr Canc, Milwaukee, WI USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Small cell lung cancer; transgenic model; RXR agonist (Bexarotene);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S943 / S943
页数：1
相关论文
共 50 条
  • [1] Preventive effect of aerosolized bexarotene in three major subtypes of lung cancer: adenocarcinoma, squamous cell carcinoma and small cell lung cancer in mice
    Zhang, Qi
    Pan, Jing
    Miller, Marker S.
    Lubet, Ronald A.
    Wang, Yian
    You, Ming
    CANCER RESEARCH, 2017, 77
  • [2] Chemoprevention of small cell lung carcinomas in mice by the retinoid X receptor agonist bexarotene
    Wang, Yian
    Wen, Weidong
    Yi, Yijun
    Zhang, Zhongqiu
    Lubet, Ronald A.
    You, Ming
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [3] A retinoid X receptor (RXR)-selective agonist bexarotene produces synergistic growth inhibitory activity with gefitinib in non-small-cell lung cancer (NSCLC) cell lines.
    Fan, B
    Negro-Vilar, A
    Lamph, WW
    Bissonnette, RP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 655S - 655S
  • [4] Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer
    Shi, Ruoshi
    Radulovich, Nikolina
    Ng, Christine
    Liu, Ni
    Notsuda, Hirotsugu
    Cabanero, Michael
    Martins-Filho, Sebastiao N.
    Raghavan, Vibha
    Li, Quan
    Mer, Arvind Singh
    Rosen, Joshua C.
    Li, Ming
    Wang, Yu-Hui
    Tamblyn, Laura
    Nhu-An Pham
    Haibe-Kains, Benjamin
    Liu, Geoffrey
    Moghal, Nadeem
    Tsao, Ming-Sound
    CLINICAL CANCER RESEARCH, 2020, 26 (05) : 1162 - 1174
  • [5] A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs
    Pan, Elizabeth
    Bogumil, David
    Cortessis, Victoria
    Yu, Sherrie
    Nieva, Jorge
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [6] Preclinical Efficacy of Vascular Disrupting Agents in Non-Small-Cell Lung Cancer
    Baguley, Bruce C.
    CLINICAL LUNG CANCER, 2011, 12 (02) : 81 - 86
  • [7] Organoid Cultures as Novel Preclinical Models of Non-Small Cell Lung Cancer
    Tsao, M.
    Shi, R.
    Radulovich, N.
    Ng, C.
    Notsuda, H.
    Cabanero, M.
    Martins-Filho, S.
    Raghavan, V.
    Li, Q.
    Mer, A.
    Liu, N.
    Pham, N.
    Haibe-Kains, B.
    Liu, G.
    Moghal, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S225 - S226
  • [8] Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes
    Zhang, Wei
    Girard, Luc
    Zhang, Yu-An
    Haruki, Tomohiro
    Papari-Zareei, Mahboubeh
    Stastny, Victor
    Ghayee, Hans K.
    Pacak, Karel
    Oliver, Trudy G.
    Minna, John D.
    Gazdar, Adi F.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (01) : 32 - +
  • [9] Prevention of lung cancer progression by bexarotene in mouse models
    Wang, Y
    Zhang, Z
    Yao, R
    Jia, D
    Wang, D
    Lubet, RA
    You, M
    ONCOGENE, 2006, 25 (09) : 1320 - 1329
  • [10] Prevention of lung cancer progression by bexarotene in mouse models
    Y Wang
    Z Zhang
    R Yao
    D Jia
    D Wang
    R A Lubet
    M You
    Oncogene, 2006, 25 : 1320 - 1329
12345